Baseline Characteristics
Baseline characteristics of patients (January 1, 2008 – September 15, 2026)
Total cohort: 38,399 patients. This table uses a different cohort count and reporting period from the Data at a Glance summary.
| Variables | Total |
|---|---|
| Total patients | 38,399 |
| Age at diagnosis | |
| < 65y | 19,931 (51.9%) |
| ≥ 65y | 18,468 (48.1%) |
| Smoking status (missing=118 (0.3%)) | |
| Never | 16,719 (43.5%) |
| Former/Current | 21,562 (56.2%) |
| Histology | |
| Non-adenocarcinoma | 9,444 (24.6%) |
| Adenocarcinoma | 28,955 (75.4%) |
| Clinical stage (missing=82 (0.2%)) | |
| I | 17,375 (45.2%) |
| II | 3,649 (9.5%) |
| III | 5,300 (13.8%) |
| IV | 11,993 (31.2%) |
| Pathologic stage | n=22,811 |
| I | 15,424 (40.2%) |
| II | 3,452 (9.0%) |
| III | 3,075 (8.0%) |
| IV | 581 (1.5%) |
| EGFR mutation | n=32,992 |
| No Mutation | 19,113 (57.9%) |
| Mutation | 13,773 (41.7%) |
| Not assessed | 106 (0.3%) |
| Del19 (L858R combine) | 6,379(10) (19.3%-all/ 46.3%-Mut) |
| L858R (del19 combine) | 5,814(10) (17.6%-all/ 42.2%-Mut) |
| Others (G719X, S768I, POL20, INS20…) | 1,590 (4.8%) |
| ALK arrangement | n=32,649 |
| Negative | 31,375 (96.1%) |
| Positive | 1,119 (3.4%) |
| Not assessed | 155 (0.5%) |
| PD-L1 (22C3, TPS) | n=22,383 (positive=6) |
| ≥50% | 4,636 (12.1%) |
| 1–49% | 5,588 (14.6%) |
| <1% | 12,131 (31.6%) |
| Not assessed | 22 (0.1%) |
| Curative intent surgery | |
| Yes (+neo adj after OP) | 20,501 (53.4%) |
| Definitive CCRT | |
| Yes | 1,932 (5.0%) |
| First line-palliative regimen | 11,993 (31.2%) |
| First line-EGFR TKI containing regimen | 3,428 (8.9%) |
| First line-ALK TKI containing regimen | 495 (1.3%) |
| First line-IO containing regimen | 1,822 (4.7%) |
| Second line-palliative regimen | 7,543 (19.6%) |
| Third line-palliative regimen | 4,095 (10.7%) |
| Others (RT only, GKS only, wedge OP, etc..) | 3,973 (10.3%) |
| NGS; Total number of NGS tests (Multiple tests per patient were counted separately) | 6,094 (15.9%) |
| Liquid NGS | 1,414 (23.2%) |
| Tissue NGS | 4,457 (73.1%) |
| Death | 16,330 (42.5%) |
| Alive (n=106 (0.3%) Death status to be confirmed) | 21,963 (57.2%) |
Footnotes
- Data are presented as n (%). EGFR exon 19 deletion and L858R percentages are shown among tested and mutation-positive patients; 10 patients with both mutations are included in both groups. ALK low expression was classified as negative. NA indicates an unavailable or uninterpretable test result. PD-L1 (22C3) is reported as TPS.
- TNM reference implementation years: seventh edition, 2010; eighth edition, 2017 internationally (AJCC, 2018); AJCC Version 9, 2025. Institutional adoption dates were not confirmed.
- Clinical and pathological stage percentages were calculated using the total cohort (N=38,399), including patients with missing stage data.
- Pathologic stage includes patients who underwent surgery after neo-adjuvant therapy.
- First-line EGFR/ALK TKI regimens are included in the first-line palliative treatment category. “Others” includes patients treated at SMC who did not meet the definitions of curative-intent surgery, definitive CCRT, or first-line palliative treatment.
Abbreviations
AJCC, American Joint Committee on Cancer; ALK, anaplastic lymphoma kinase; CCRT, concurrent chemo-radiotherapy; EGFR, epidermal growth factor receptor; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; PCR, polymerase chain reaction; PD-L1, programmed death-ligand 1; TKI, tyrosine kinase inhibitor; TNM, tumor–node–metastasis; TPS, tumor proportion score; WT, wild type.